A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
This clinical trial is designed to include two parts:
Part 1: Assessment of feasibility and safety of administering YM155 in combination with
docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) [
ENROLLMENT COMPLETED ]
Part 2: Assessment of feasibility and safety of administering YM155 in combination with
docetaxel in subjects with solid tumors (except HRPC).
This registration has been updated to reflect the design requirements of PART 2.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Occurrence of dose limiting toxicities (Part 1: Subjects with HRPC)
Astellas Pharma Global Development
United States: Food and Drug Administration
|Austin, Texas 78705|